Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zeren
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  InMed Pharmaceuticals ... stage biopharmaceutical company that specializes in developing safer, ... of Paul C. Anderson , Ph.D., to ... pharma industry veteran who brings significant drug discovery ... Anderson is a synthetic organic chemist by training ...
(Date:3/31/2015)... -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) ... and 300mg oral tablets, indicated for use in the ... Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 ... Arthur S. Przybyl , President and Chief Executive Officer ... our fourth product from the portfolio of approved generic ...
(Date:3/31/2015)... March 31, 2015  Oxis International, Inc. (OXIS) (OXI.PA) ... and commercialization, announced today Oxis CEO Tony Cataldo ... Oxis common shares on the Euronext exchange. Oxis shares ... symbol OXIS.   Oxis Chairman and CEO ... move forward with its strategies launched in 2014 and ...
Breaking Medicine Technology:InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Oct. 7 Cleveland Clinic,s Top 10 Medical Innovations for ... therapies that are being developed to treat everything from deafness ... The list of breakthrough devices and therapies was selected by ... was unveiled during Cleveland Clinic,s 2009 Medical Innovation ...
... Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today ... offering of 3.97 million shares of its common stock to ... gross proceeds of $3.97 million. , The shares were ... with the Securities and Exchange Commission that was declared effective ...
Cached Medicine Technology:Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 2Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 3Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 4Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering 2
(Date:3/31/2015)... Indosoft, developer of the Q-Suite call center ... development of their 5.x line. The industry leading contact ... around the world for more than a decade. By announcing ... platform, Q-Suite can fully embrace newer Asterisk features and improve ... on Asterisk for more than a decade. The use of ...
(Date:3/31/2015)... Phoenix, AZ (PRWEB) March 31, 2015 The ... on the GMO controversy , just kicked off their ... oft-controversial term “substantial equivalence.” , “ Substantial Equivalence was ... United States,” states Eric Battersby, Director at Change The World ... to a point well before GMOs even entered our food ...
(Date:3/31/2015)... Plains, NJ (PRWEB) March 31, 2015 Dr. ... Institute for Advanced Reconstruction. He was recently quoted in ... is caused by lymphatic issues, causing fluid retention and tissue ... the procedure to relieve and / or improve lymphedema symptoms. ... to improve or alleviate the symptoms of lymphedema. The ...
(Date:3/31/2015)... March 31, 2015 Researchers at ... mice and humans: how human livers heal. The ... activates liver regeneration. Normally, mouse PPARa is far ... allowing mice to quickly regenerate damaged livers. However, ... 21 (FGF21) can boost the regenerative effects of ...
(Date:3/31/2015)... Indosoft, Inc., developers of contact center software ... SIP over TCP configuration for all SIP devices in Q-Suite ... contact center ACD (Automatic Call Distributor) system on ... TCP support to all SIP devices gives users an additional ... Voice over IP (VoIP) has primarily involved User Datagram Protocol ...
Breaking Medicine News(10 mins):Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:The Walk a Mile Project Launches New Research Sequence on Substantial Equivalence of GMOs 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 3Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 4Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 2Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 3Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 4Health News:Indosoft extends SIP over TCP support to User Extensions in its Q-Suite 5.9 Call Center Software 2
... addressed more aggressively, study says , , THURSDAY, May 22 ... lung function faster and more significantly as they age, ... age, according to new research. , Contrary to ... a restrictive rather than obstructive or asthma-like pattern. ...
... 22, 2008) - What common oral condition appears as ... Americans, can be caused by food allergies and hormonal ... Commonly referred to as canker sores, recurrent aphthous ulcers ... licorice root herbal extract, according to a study published ...
... exchanging a tooth for that coveted reward from the tooth ... happens when a primary or permanent tooth is lost prematurely ... March/April 2008 issue of General Dentistry, the AGDs clinical, peer-reviewed ... know what to do with a traumatically affected tooth and ...
... New Rochelle, NY, May 22, 2008 The Home ... to a $5.6 billion level and will continue to ... next three to five years, according to a new ... Ann Liebert company. Insight and Intelligence interviewed industry leaders, ...
... May 22 Medtronic Spine LLC, the,corporate successor ... United States $75,million to settle allegations that it ... Justice Department announced today. The government alleged,that Kyphon ... kyphoplasty,procedure, which is a minimally-invasive surgery used to ...
... 22 The California,Senate rejected a bill today sponsored ... its name after privacy violations. See Washington Post,coverage below., ... a second chance to pass,the Senate and will be ... in,existing law which bars the sharing of private medical ...
Cached Medicine News:Health News:Lung Trouble Associated With Sickle Cell in Kids 2Health News:Licorice extract provides new treatment option for canker sores 2Health News:Premature tooth loss can affect oral health for years to come 2Health News:Medtronic Spine, Formerly Kyphon Inc., to Pay U.S. $75 Million to Resolve Allegations Of Defrauding Medicare 2Health News:Sponsor of Drug Bill Rejected by CA Senate Today Changed Its Name After Privacy Violations 2Health News:Sponsor of Drug Bill Rejected by CA Senate Today Changed Its Name After Privacy Violations 3
Instrument set for carpal tunnel release....
Standard arthroscopy graspers for small joints. Also available are Mosquito Tip Graspers, 45 degree Forceps, SquareTrimmer Blunt Tip Forceps and SST Scoop Tip Forceps....
... SR™ Hand Implant System utilizes the same ... joint replacements. The SR™ Hand Implant ... other prostheses including minimal bone resection, surface ... articular surfaces, retention and/or repositioning of the ...
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
Medicine Products: